- With the New Dalriada Partnership, Champignon Expects to Develop a Robust Pipeline of Preclinical and Clinical Assets with Strong IP Protection
- Dalriada’s Medicinal Chemistry Expertise Combined with Champignon’s Innovative Formulation Platforms Will Accelerate the Company’s Advancement of Therapeutic Applications of Ketamine and Psilocybin Derivatives
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FRA: 496) announced Monday it selected Dalriada Drug Discovery to advance the company’s new chemical entity (NCE) IP portfolio of ketamine and psilocybin/psilicin molecular scaffolds.
Dr. Roger McIntyre, CEO of Champignon Brands, a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, commented on Monday’s announcement:
“Champignon has developed a comprehensive working arrangement with Dalriada focusing on R&D. Dalriada is aligned with Champignon with respect to quality, efficiency, and their results-oriented approach. We are highly confident that our partnership with Dalriada will provide a series of assets that will be available for our near-term, preclinical, Phase I and Phase II testing pursuits.”
Dalriada Drug Discovery, a leading contract research organization in the drug discovery space, will support Champignon Brands in the following ways:
- Dalriada will lead Champignon’s new drug discovery programs in the NCE arena.
- Dalriada will also provide integrated R&D support to accelerate Champignon’s existing preclinical assets and ongoing development of proprietary delivery platforms.
- With the new partnership, Champignon expects to develop a robust pipeline of preclinical and clinical assets with strong IP protection.
Dr. Joseph Gabriele, a special advisor to Champignon Brands, stated:
“It is with great pleasure that we welcome the Dalriada group to Champignon. Dalriada’s expertise in medicinal chemistry will be a monumental addition to Champignon’s innovative, diverse formulation platforms by their expertise in the synthesis of molecules, including existing psychedelics (ketamine, psilocybin and MDMA), as well as novel new psychedelic-like molecules. This synergistic collaboration will differentiate Champignon from other companies in the psychedelic space by boosting our ability to maintain an in-house infrastructure for the clinical delivery NCEs.”
“We are excited to support Champignon’s innovative work in advancing the therapeutic applications of ketamine and psilocybin derivatives. Champignon’s pioneering approach to the use of these agents for the treatment of depression and other indications with high unmet need holds a lot of promise. We are delighted to complement their strong scientific and management team with our expertise in small molecule drug discovery, and help Champignon expand their current asset portfolio,” said Dalriada Drug Discovery CEO Dr. Diana Kraskouskaya.
Learn More About Dalriada Drug Discovery
Dalriada, through its TURN-KEY™ Drug Discovery services model, provides a full suite of drug discovery, medicinal chemistry and intellectual property services for semi-virtual, lean biotechnology clients that focus on developing small molecule therapies. With R&D operations in Mississauga, Canada, Dalriada builds focused teams with expertise in MedChem, Biology and ADME to allow for the most rapid and cost-effective project execution and value building. One of the Dalriada’s niche expertise is in the development of novel covalent therapeutics for which Dalriada developed a proprietary screening platform, spearheaded by its CSO and co-founder, Dr. Patrick Gunning. Visit Dalriada Drug Discovery’s Website Here
Champignon Brands Corporate Profile Video
SHRM Stock Price Action & Chart
Shares of Champignon’s CSE listed SHRM stock rallied 4.42% on Monday to close the day at $1.18 per share. The company’s U.S. SHRMF shares jumped 5.88% to close Monday’s session at $0.90. Overseas in Germany, Champignon’s Frankfurt listed stock closed the day at $0.845, up 6.96%.
Champignon Brands is a paid client of The Cannabis Investor. The Cannabis Investor holds a position in Champignon Brands.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.